Rankia España Rankia Argentina Rankia Brasil Rankia Chile Rankia Colombia Rankia Czechia Rankia Deutschland Rankia France Rankia Indonesia Rankia Italia Rankia Magyarország Rankia México Rankia Netherlands Rankia Perú Rankia Polska Rankia Portugal Rankia Romania Rankia Türkiye Rankia United Kingdom Rankia USA
Acceder

Farmas USA

135K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
7.608 / 16.979
#60857

Re: Farmas USA

Acerca de los biosimilares (de "El Economista" de hoy 30/3)...

El Economista 30/3/2015

El Economista 30/3/2015

#60858

Re: Farmas USA

El CEO de HZNP Tim Walbert es un genio, ahora va a por Orphan drugs

#60859

Re: Farmas USA

Patron buyout a partir de ahora.

#60862

Re: Farmas USA

Teva Pharma (TEVA) to Acquire Auspex Pharma (ASPX) in $3.2B Deal

Teva Pharma (NYSE: TEVA) and Auspex Pharmaceuticals, Inc. (Nasdaq: ASPX), today announced that they have entered into a definitive merger agreement under which Teva will commence a tender offer for all of the outstanding shares of Auspex at $101.00 per share in cash, representing total consideration of approximately $3.2 billion in enterprise value and approximately $3.5 billion in equity value. This transaction is expected to enhance Teva’s revenue and earnings growth profile and strengthen its core central nervous system (CNS) franchise with the addition of Auspex’s portfolio of innovative medicines for people who live with movement disorders. The transaction has been unanimously approved by the Boards of Directors of both Teva and Auspex, and key shareholders of Auspex have entered into agreements indicating their support for the transaction.

Auspex is an innovative biopharmaceutical company specializing in applying deuterium chemistry to known molecules to create novel therapies with improved safety and efficacy profiles. Its lead investigational product, SD-809 (deutetrabenazine), which leverages Auspex’s deuterium technology platform is being developed for the potential treatment of chorea associated with Huntington’s disease, tardive dyskinesia, and Tourette syndrome, with a pharmacokinetic profile that allows for lower doses resulting in a favorable safety profile.

In 2014, Auspex reported positive results from its Phase 3 clinical trial for SD-809 in Huntington’s disease, with plans to submit a New Drug Application (NDA) for this indication by mid-2015. SD-809 has been granted orphan drug designation for the treatment of Huntington's disease by the United States Food and Drug Administration (FDA), and Auspex expects regulatory approval and commercial launch for this indication in 2016 in the United States. Topline results for Auspex’s Phase 3 ARM-TD study of SD-809 as a potential treatment for tardive dyskinesia, a disorder for which there are no approved therapies, are also expected in mid-2015. Other pipeline candidates include deuterated versions of pirfenidone for idiopathic pulmonary fibrosis and levodopa for Parkinson’s disease. Auspex has an additional 60 molecules in its patent portfolio

Otra con el Patrón Buyout.

http://stockcharts.com/h-sc/ui?s=ASPX&p=D&st=2014-12-30&en=today&id=p82478150358

#60863

Re: Farmas USA

Desde los 25$ de mediados Diciembre!!!

ASPX

De nuevo me ratifico en la idea de que el IBB esta donde esta porque se lo merece y nadie le ha regalado nada.

Con toda la ristra de OPAs de 2014 y ahora las que empiezan a llegar en 2015 solo veo un sector biotech llegando a un punto en el que esta consolidando su posicion ( 50 puntos arriba o abajo me dan igual ), adaptandose a la nueva situacion, opas y mas opas ... para seguir creciendo.

El sector se adapta.

#60864

Re: Farmas USA

Por cierto Auxpex es una bio con productos en las fases finales ensayo pero aún sin productos aprobados.
Van a pagar por ella 3.200 millones de dólares... Y dudo que tenga un pipeline con el potencial económico que tiene Novavax contando sólo su programa de vacunas para el RSV.
Por tener perspectiva digo....

Guía Básica
Brokers destacados